Abstract: Novel cyclic pentapeptides, WS7338A, B, C and D [cyclo-(AAl -AA2-DTrp-D-Glu-Ala)] were isolated as Endothelin (ET) receptor antagonists from the culture broth of Sfreptomyces sp. No. 7338. Based on conformational analysis of these seeds, we defined the minimum structural requirements for binding affinity and prepared a series of acylated tripeptides with ETA receptor binding affinity. Through extensive chemical modification of the lead tripeptide, we have discovered a highly potent and selective ETA receptor antagonist FR139317. Further modification of this series of tripeptide ET antagonists has led to the discovery of a highly potent and selective ETB receptor antagonist FR164343. The discovery and structure-activity relationship of these ET antagonists and the pharmacological profile of FR139317 and FR164343 are described.
Introduction
Endothelin 1 (ET-l), which consists of 21 amino acid residues with two disulfide bonds, was first isolated from cultured porcine vascular endothelial cells in 1988 and has been found to be the most potent and long-lasting vasoconstrictor peptide (1) . Subsequently, a family of mammalian ET isopeptides (ET-1, ET-2 and ET-3) has been identified (2). ET receptors have been divided into two different subtypes, ETA (ET-1 selective) and ETB (nonselective for the isopeptides) (3, 4) . ETA receptors are distributed predominantly in vascular smooth muscle, heart and intestine, whereas ETB receptors are found in cerebral cortex, kidney and trachea. ETs have been implicated in the pathogenesis of several disease states such as hypertension, acute myocardial infarction, renal failure and asthma (5). Therefore the discovery of receptor subtype selective antagonists will help to clarify the pathophysiological roles of ETs and should also give potentially useful therapeutic agents.
In the course of our screening program we discovered novel four ET receptor antagonists, WS7338A 1, B 2, C 3 and D 4 in the culture broths of Streptomyces sp. No. 7338 (6) . The structure and antagonistic activities of these compounds in the ET receptor binding assay are shown in Table 1 . Activity at the ETA receptor was measured by inhibition of 1251-labeled ET-1 binding to porcine aorta membranes. Activity at the E?B receptor was measured by inhibition of 125I-labeled ET-1 binding to porcine kidney membranes. These results indicated that WS7338B 2 is the most potent and selective ETA receptor antagonist among these WS 7338 compounds (7). 
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Conformation analysis on the basis of NMR data revealed that 2 was stabilized by two intramolecular hydrogen bonds as judged by the presence of two amide protons showing small temperature coefficients (AG/AT[ppb/deg]: D-alloIle (1.7), D-Glu (1.9)) (8, 9) . These results suggested that the hydrogen bonds Glu NH to alloIle C-0 and alloIle NH to Glu C-0 form a type I1 p-turn in the D-alloIle-Leu-D-Trp-D-Glu region and an inverse y-turn in the D-Glu-Ala-D-alloIle region (Figure 1 ). Using this information regarding peptide backbone conformation as the starting point, we designed linear peptide derivatives. (10, 11) . We attempted to define the minimum structural requirements on cyclic pentapeptides for ETA receptor binding, prior to an investigation of the structure-activity relationships of WS7338 compounds and their related cyclic peptide analogues. We first synthesized five different linear pentapeptides 5 , 6 , 7 , 8 and 9, and examined the binding affinity ( Figure  2 ). Among these five linear pentapeptide derivatives, 5,6 and 7 were found to retain almost equal potent binding affinity to the parent cyclic pentapeptide 2. In contrast, 8 and 9 were completely inactive.
h-5 100: 0.33pM We therefore selected 12 as a new lead and extensively modified this compound.
A Highly Potent and Selective ETA Receptor Antagonist FR139317
In order to discover a more potent antagonist, we attempted to optimize the new lead tripeptide derivative 12 (12) . First, the D-Glu(OBz1) part was converted into other amino acid residues (Table 2) . To investigate whether the hydrophobicity of the Bzl ester group had an important role on binding affinity, we prepared substituted derivatives with an achiral amino acid, p-Ala 13, an aliphatic amino acid, D-Leu 14 and an aromatic amino acid, D-Phe 15. The activity of &Ala 13 was to some extent attenuated, whereas 14 and 15 were more potent than 12. Replacement of D-Phe in 15 with D-2-pyridylalanine (D-2-Pya) 16 resulted in a remarkable increase in potency with an ICSO value of 7.0 nM, and in water solubility. Second, the Leu part was converted into other amino acid residues (Table 3) . However, the substitution of Leu in 13 with Ile 17 and NIe 18, which are structural isomers of Leu, gave compounds with much lower activity compared with 13. Effects on the substitution of D-Trp(Me) are listed in Table 4 
This demonstrated that the incorporation of the urea group resulted in the higher activity than the corresponding amide derivative 16. Based on this data, a variety of urea analogues were synthesized. The compounds substituted with cyclohexylaminocarbonyl24, N-cyclohexyl-N-methyl-aminocarbonyl25 and N,N-di-n-propylaminocarbonyl26 maintained more potent binding affinity. Among these compounds, the cyclic iminocarbonyl derivative, hexamethyleneiminocarbonyl 27 (FR1393 17) exhibited significantly higher affinity with an IC50 value in the 1O-loM range. Therefore, we selected the most potent and highly water soluble tripeptide derivative 27 (FR139317) (IC50: 0.53 nM for ETA and 3200 nM for ETB; solubility: > 100 mg/ml as the sodium salt) for further pharmacological evaluation.
From the structure-activity relationships on 27 FR139317 and its related derivatives, it may be concluded that the Leu-D-Trp(Me) part in the p-turn region probably contributes to the ETA receptor binding and that both the N-terminal hexamethyleneiminocarbonyl group and the C-terminal D-2-Pya residue may play important roles for stabilizing the p-turn structure.
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A Highly Potent and Selective ETB Receptor Antagonist FR164343
During modification of the lead tripeptide antagonists, we encountered an antagonist 28 [2-chlorophenyl-
acetyl-Leu-D-Trp(Me)-D-Leu-OH]
that had relatively high affinity for the E'IB receptor (IC50: 32 nM for ETA and 210 nM for E n ) . On the basis of this observation, we started to design selective ETB receptor antagonists (13). First, the D-Trp(Me) part in 28 was modified ( Table 6 ) Table 7) . Among these compounds, the replacement with D-Val33 considerably increased ETB affinity, but retained weak ETA affinity. From these results, we speculated that the increased ETB selectivity might be due to a conformational change in the p-turn region by the N-terminal 2-chlorophenylacetyl group and the p-branched alkyl side chain of the C-terminal D-Val residue. We therefore introduced an N-methyl group to the N-terminal Leu residue in order to disturb the formation of an intramolecular hydrogen bond in the p-turn region. As predicted, 2-chlorophenylacetyl-N-MeLeu-D-1 -Nal-D-Val-OH 34 retained high ETB affinity and completely abolished ETA affinity (Table 8) . While its selectivity and potency were very attractive, the poor water solubility of compound 34 was found to limit its usefulness in further pharmacological evaluation.
Finally, we tried to Optimize the N-Me moiety in 34 to improve water solubility ( 
Pharmacological Profile of ET Receptor Antagonists
Our efforts to optimize the natural cyclic pentapeptide linear tripeptide ETA antagonist FR1393 17 and a novel linear tripeptide ETB antagonist FR164343. We next investigated the pharmacological profile of these expressed in CHO cells was determined (Table 9) .
From these results it has been confirmed that FR139317 is a highly potent and selective ETA receptor antagonist, whereas FR164343 is a highly potent and selective ETB antagonist. We examined the effect of FR139317 on the changes in blood pressure induced by ET-1 in conscious rat. An intravenous bolus injection of ET-1 induced a biphasic response consisting of a transient fall in blood pressure followed by a sustained pressor response. FR1393 17 dose-dependently inhibited the pressor response ( Figure 3 ). In contrast, even at the highest dose it did not show any effect on the initial depressor response mediated by the ETB receptor. This data demonstrated that FR139317 is effective in blocking ETA receptor-mediated responses ( 14) .
WS 7338 B 2 have led to the discovery of a novel antagonists. Binding to human ETA and ETB receptors Furthermore, we evaluated the effect of FR164343 on bronchoconstriction induced by ET-1 in anesthetized guinea pigs. An intravenous bolus injection of ET-1 induced a transient bronchoconstriction. This response is mainly mediated by the ETB receptor (15) . FR164343, a highly potent ETB receptor antagonist, inhibited the bronchoconstrictor response in a dose-dependent manner (Figure 4 ). In the same model, FR139317 (1 mg/kg, i.v.) did not show any effect on bronchoconstrictor response. These results demonstrate that FR164343 is effective in blocking ETB receptor mediated bronchoconstriction in guinea pigs.
Conclusion
Through extensive modification of the cyclic pentapeptide 2 on the basis of its conformation analysis, we have discovered a series of tripeptide ET receptor antagonists with ETA and ETB subtype-selectivity. Further in vivo characterization demonstrated that FR139317 is a highly potent and selective ETA receptor antagonist, whereas FR164343 is a highly potent and selective ETB receptor antagonist. It may be concluded that FR139317 and FR164343 are useful pharmacological agents for investigating the pathophysiological roles of the ET system.
